✦ LIBER ✦

Once-Daily Intravenous Busulfan with Therapeutic Drug Monitoring Compared to Conventional Oral Busulfan Improves Survival and Engraftment in Children Undergoing Allogeneic Stem Cell Transplantation

✍ Scribed by Imke H. Bartelink; Robbert G.M. Bredius; Tessa T. Ververs; Martine F. Raphael; Charlotte van Kesteren; Marc Bierings; Carin M.A. Rademaker; J. den Hartigh; Cuno S.P.M. Uiterwaal; Juliette Zwaveling; Jaap J. Boelens

Book ID: 116279782
Publisher: Elsevier Science
Year: 2008
Tongue: English
Weight: 293 KB
Volume: 14
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2007.09.015

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

229: Twice-Daily Intravenous (IV) Busulf

229: Twice-Daily Intravenous (IV) Busulfan (Bu) x 4 Days in Children Undergoing a Reduced-Intensity Conditioning (RIC) Regimen with Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT) is Safe and Well-Tolerated but Results in Significantly Increased Bu Clearance (CL) and Decreased Area Under the Curve (AUC) and Half-Life (t1/2) When Compared to IV Bu Twice-Daily Dosing Pharmacokinetics (PK) in Adults

✍ I. Waxman; M. Bhatia; M. Milone; L.M. Shaw; L. Baldinger; O. Militano; J. Garvin 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 60 KB